Aclaris Therapeutics Inc
ACRS1.535USD
+0.005+0.33%
Market hours （ET）Quotes delayed by 15 min
166.19MMarket Cap
LossP/E TTM
More Details of Aclaris Therapeutics Inc Company
Aclaris Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases. The Company has a multi-stage portfolio of drug candidates powered by a robust research and development engine exploring protein kinase regulation. Its segments include therapeutics and contract research. The therapeutics segment is focused on identifying and developing therapies to address unmet needs for immuno-inflammatory diseases and providing licensing of its intellectual property. The contract research segment provides laboratory services. The Company's KINect drug discovery platform combined with its preclinical development capabilities allows it to identify and advance potential drug candidates that it may develop independently or in collaboration with third parties. The Company's drug candidates include ATI-1777, ATI-2138 and Zunsemetinib. ATI-1777 is an investigational topical soft Janus kinase, or JAK, 1/3 inhibitor.
Company Info
Ticker SymbolACRS
Company nameAclaris Therapeutics Inc
IPO dateOct 07, 2015
CEODr. Neal S. Walker
Number of employees64
Security typeOrdinary Share
Fiscal year-endOct 07
Address701 Lee Road
CityWAYNE
Stock exchangeNASDAQ Global Select Consolidated
CountryUnited States of America
Postal code19087
Phone14843247933
Websitehttps://www.aclaristx.com/
Ticker SymbolACRS
IPO dateOct 07, 2015
CEODr. Neal S. Walker
Company Executives
Name
Name/Position
Position
Shareholding
Change
Mr. James (Jim) Loerop
Mr. James (Jim) Loerop
Chief Business Officer
Chief Business Officer
103.31K
+21.18%
Mr. Christopher P. Molineaux
Mr. Christopher P. Molineaux
Lead Independent Director
Lead Independent Director
57.96K
+9.02%
Mr. William Douglas Humphries
Mr. William Douglas Humphries
Independent Director
Independent Director
33.52K
+16.68%
Dr. Maxine Gowen, Ph.D.
Dr. Maxine Gowen, Ph.D.
Independent Director
Independent Director
21.75K
+28.26%
Mr. Vincent J. Milano
Mr. Vincent J. Milano
Independent Director
Independent Director
17.32K
+38.27%
Dr. Andrew N. (Drew) Schiff, M.D.
Dr. Andrew N. (Drew) Schiff, M.D.
Independent Director
Independent Director
13.96K
+52.29%
Mr. Kevin Balthaser
Mr. Kevin Balthaser
Chief Financial Officer
Chief Financial Officer
--
--
Dr. Neal S. Walker
Dr. Neal S. Walker
Non-Executive Chairman of the Board, Chief Executive Officer, Co-Founder
Non-Executive Chairman of the Board, Chief Executive Officer, Co-Founder
--
--
Dr. Hugh M. Davis, Ph.D.
Dr. Hugh M. Davis, Ph.D.
President, Chief Operating Officer, Director
President, Chief Operating Officer, Director
--
--
Dr. Anand Mehra, M.D.
Dr. Anand Mehra, M.D.
Independent Director
Independent Director
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Mr. James (Jim) Loerop
Mr. James (Jim) Loerop
Chief Business Officer
Chief Business Officer
103.31K
+21.18%
Mr. Christopher P. Molineaux
Mr. Christopher P. Molineaux
Lead Independent Director
Lead Independent Director
57.96K
+9.02%
Mr. William Douglas Humphries
Mr. William Douglas Humphries
Independent Director
Independent Director
33.52K
+16.68%
Dr. Maxine Gowen, Ph.D.
Dr. Maxine Gowen, Ph.D.
Independent Director
Independent Director
21.75K
+28.26%
Mr. Vincent J. Milano
Mr. Vincent J. Milano
Independent Director
Independent Director
17.32K
+38.27%
Dr. Andrew N. (Drew) Schiff, M.D.
Dr. Andrew N. (Drew) Schiff, M.D.
Independent Director
Independent Director
13.96K
+52.29%
Revenue Breakdown
Currency: USDUpdated: Sun, Jul 6
Currency: USDUpdated: Sun, Jul 6
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
FY2020
FY2018
By BusinessUSD
Name
Revenue
Proportion
Licensing
1.01M
69.42%
Laboratory Research Revenue
445.00K
30.58%
No Data
By Business
By Region
By BusinessUSD
Name
Revenue
Proportion
Licensing
1.01M
69.42%
Laboratory Research Revenue
445.00K
30.58%
Shareholding Stats
Updated: Sat, May 17
Updated: Sat, May 17
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
BML Capital Management LLC
13.16%
Adage Capital Management, L.P.
8.89%
Vivo Capital, LLC
8.21%
The Vanguard Group, Inc.
6.15%
Rock Springs Capital Management LP
4.66%
Other
58.93%
Shareholders
Shareholders
Proportion
BML Capital Management LLC
13.16%
Adage Capital Management, L.P.
8.89%
Vivo Capital, LLC
8.21%
The Vanguard Group, Inc.
6.15%
Rock Springs Capital Management LP
4.66%
Other
58.93%
Shareholder Types
Shareholders
Proportion
Investment Advisor
27.72%
Hedge Fund
27.24%
Venture Capital
18.30%
Investment Advisor/Hedge Fund
10.34%
Research Firm
3.75%
Individual Investor
2.69%
Pension Fund
0.39%
Other
9.57%
Institutional Shareholding
Updated: Tue, Jul 1
Updated: Tue, Jul 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q2
321
97.92M
90.43%
-39.77M
2025Q1
348
97.22M
89.83%
-39.83M
2024Q4
345
91.46M
84.84%
-21.09M
2024Q3
339
54.07M
75.01%
-55.64M
2024Q2
343
56.87M
79.07%
-55.28M
2024Q1
324
57.53M
81.03%
-59.90M
2023Q4
334
60.83M
85.72%
-31.33M
2023Q3
329
72.95M
103.11%
-12.25M
2023Q2
327
74.07M
104.78%
-6.71M
2023Q1
338
74.82M
111.43%
+1.42M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
BML Capital Management LLC
14.25M
13.16%
--
--
Mar 31, 2025
Adage Capital Management, L.P.
9.63M
8.89%
--
--
Mar 31, 2025
Vivo Capital, LLC
8.89M
8.21%
--
--
Mar 31, 2025
The Vanguard Group, Inc.
4.97M
4.59%
+644.99K
+14.91%
Mar 31, 2025
Rock Springs Capital Management LP
5.05M
4.66%
-1.16M
-18.66%
Mar 31, 2025
RA Capital Management, LP
4.67M
4.31%
--
--
Mar 31, 2025
Decheng Capital LLC
4.04M
3.73%
+1.78M
+78.31%
Mar 31, 2025
Millennium Management LLC
5.54M
5.12%
+1.41M
+34.08%
Apr 28, 2025
D. E. Shaw & Co., L.P.
2.94M
2.72%
-349.11K
-10.60%
Mar 31, 2025
Morgan Stanley & Co. LLC
2.41M
2.22%
+1.34M
+125.34%
Mar 31, 2025
View more
Related ETFs
Updated: Sat, Aug 2
Updated: Sat, Aug 2
Name
Proportion
Invesco NASDAQ Future Gen 200 ETF
0.44%
iShares Micro-Cap ETF
0.03%
iShares Russell 2000 Value ETF
0.01%
ProShares Hedge Replication ETF
0.01%
Global X Russell 2000 ETF
0.01%
Proshares Ultra Russell 2000
0.01%
ProShares UltraPro Russell2000
0.01%
Schwab U.S. Broad Market ETF
0%
iShares ESG Aware MSCI USA Small-Cap ETF
0%
Schwab U.S. Small-Cap ETF
0%
View more
Invesco NASDAQ Future Gen 200 ETF
Proportion0.44%
iShares Micro-Cap ETF
Proportion0.03%
iShares Russell 2000 Value ETF
Proportion0.01%
ProShares Hedge Replication ETF
Proportion0.01%
Global X Russell 2000 ETF
Proportion0.01%
Proshares Ultra Russell 2000
Proportion0.01%
ProShares UltraPro Russell2000
Proportion0.01%
Schwab U.S. Broad Market ETF
Proportion0%
iShares ESG Aware MSCI USA Small-Cap ETF
Proportion0%
Schwab U.S. Small-Cap ETF
Proportion0%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
